Abstract 3258
Background
New therapeutic concepts have led to substantial improvement in the survival of cancer patients. Yet, due to their compromised immune system these patients are at increased risk to encounter infections and need particular care with regard to vaccine preventable diseases (VPDs). Decreased seroprevalence to VPDs has already been reported in children suffering from malignancies, yet data from adult cancer patients are scarce. Here, we examined the antibody (Ab) titers as well as seronegativity levels against common VPDs in adults with cancer and compared them to healthy controls.
Methods
Abs mounted against measles, mumps, rubella, varicella, hepatitis A and B, diphtheria, tetanus, pertussis and tick-borne encephalitis (TBE) were evaluated in sera from 478 cancer patients and 117 age- and gender-matched controls by standard ELISAs.
Results
Compared to controls, significantly lower Ab levels against 5 out of the 10 investigated VPDs (p < 0.05), i.e. measles, hepatitis B, diphtheria, tetanus and TBE, were found in patients with solid cancers (SC), while patients with haematological cancers (HC) had significantly lower antibody titers against all 10 examined VPDs (p < 0.05). In accordance, compared to controls, cancer patients had increased seronegativity rates against VPDs, of which those against diphtheria (41% in SC patients and 76% in HC patients), hepatitis B (74% in SC patients and 87% in HC patients) and pertussis (75% in SC patients and 91% in HC patients) were the highest.
Conclusions
Patients with SC and HC have lower antibody titers and higher seronegativity rates against the most common VPDs compared to the general population. Thus, in order to prevent severe infections in this patient group, the vaccination status as well as vaccination programs need to be routinely implemented into oncological treatment concepts.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Ursula Wiedermann.
Funding
Institute of Specific Prophylaxis and Tropical Medicine, Medical University of Vienna.
Disclosure
A.S. Berghoff: Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Daiichi Sankyo; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: Roche; Honoraria (self), Advisory / Consultancy: Bristol-Meyers Squibb; Honoraria (self), Advisory / Consultancy: Merck; Travel / Accommodation / Expenses: Amgen; Travel / Accommodation / Expenses: AbbVie. C.C. Zielinski: Honoraria (self), Advisory / Consultancy, Member of scientific advisory board until September 2018: Imugene; Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), institution: Central European Cooperative Oncology Oncology Group (CECOG): BMS; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), institution: Central European Cooperative Oncology Oncology Group (CECOG): MSD; Honoraria (self), Advisory / Consultancy: Ariad; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), institution: Central European Cooperative Oncology Oncology Group (CECOG): Pfizer; Honoraria (self), Advisory / Consultancy: Merrimack; Honoraria (self), Advisory / Consultancy: Merck KGaA; Honoraria (self), Advisory / Consultancy: Fibrogen; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), institution: Central European Cooperative Oncology Oncology Group (CECOG): AstraZeneca; Honoraria (self), Advisory / Consultancy: Tesaro; Honoraria (self), Advisory / Consultancy: Gilead; Honoraria (self), Advisory / Consultancy: Servier; Honoraria (self), Advisory / Consultancy: Shire; Honoraria (self), Advisory / Consultancy: Eli Lilly; Honoraria (self), Advisory / Consultancy: Athenex. U. Wiedermann: Research grant / Funding (institution), Officer / Board of Directors, CSO until October 2018: Imugene; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): GSK; Research grant / Funding (institution): Themis. All other authors have declared no conflicts of interest.
Resources from the same session
4526 - Long-term outcome of neoadjuvant tyrosine kinase inhibitors (TKI) in locally advanced dermatofibrosarcoma protuberans (DFSP)
Presenter: Jessica Beaziz
Session: Poster Display session 1
Resources:
Abstract
1214 - Neo-adjuvant (NA) Imatinib for gastrointestinal stromal tumours (GISTs): What is the optimal length of treatment?
Presenter: Tom Wilson
Session: Poster Display session 1
Resources:
Abstract
2690 - Gastrointestinal Stromal Tumours (GIST) in adolescents and young adults (AYA)
Presenter: Nikki Ijzerman
Session: Poster Display session 1
Resources:
Abstract
4558 - Radiomics improves response evaluation for desmoid tumors treated with chemotherapy
Presenter: Amandine Crombe
Session: Poster Display session 1
Resources:
Abstract
2751 - Radiomics of gastrointestinal stromal tumors; risk classification based on computed tomography images – a pilot study
Presenter: Milea Timbergen
Session: Poster Display session 1
Resources:
Abstract
2737 - Differentiating well-differentiated liposarcomas from lipomas using a radiomics approach
Presenter: Melissa Vos
Session: Poster Display session 1
Resources:
Abstract
1282 - The immune landscape of chondrosarcoma reveals an anti inflammatory environment
Presenter: Iseulys Richert
Session: Poster Display session 1
Resources:
Abstract
1572 - Impact of Immunotherapy and Targeted Therapy on Tumor Growth Rate in Sarcoma
Presenter: Esmail Al-ezzi
Session: Poster Display session 1
Resources:
Abstract
3414 - DNA methylation profiles of angiosarcoma subtypes.
Presenter: Marije Weidema
Session: Poster Display session 1
Resources:
Abstract
3411 - Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As and BTN3A1 in patients with metastatic gastrointestinal stromal tumors (mGISTs)
Presenter: Daniele Fanale
Session: Poster Display session 1
Resources:
Abstract